LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer
Cyclin D1 is involved in tamoxifen resistance in breast cancer (BC) but how it is regulated is unclear. Here, the authors demonstrate that the LncRNA DILA1 contributes to tamoxifen resistance in breast cancer by binding to Cyclin D1 and preventing its degradation.
Guardado en:
Autores principales: | Qianfeng Shi, Yudong Li, Shunying Li, Liang Jin, Hongna Lai, Yanqing Wu, Zijie Cai, Mengdi Zhu, Qian Li, Ying Li, Jingru Wang, Yujie Liu, Zongqi Wu, Erwei Song, Qiang Liu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/37f72cf52027467ca19fd566a8fd2abd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1
por: Yinghua Zhu, et al.
Publicado: (2018) -
LncRNA ATXN8OS enhances tamoxifen resistance in breast cancer
por: Zhang Hongkai, et al.
Publicado: (2020) -
LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway
por: Ang Gao, et al.
Publicado: (2018) -
MicroRNA-195 inhibits the proliferation of human glioma cells by directly targeting cyclin D1 and cyclin E1.
por: Wang Hui, et al.
Publicado: (2013) -
LncRNA SAMD12-AS1 promotes cell proliferation and inhibits apoptosis by interacting with NPM1
por: Qi Liu, et al.
Publicado: (2019)